World’s most trusted Companion Diagnostic testing for Personalized Cancer treatments
351 Clinically Significant Onco Genes
Trusted by over 10000+ oncologists globally
Sequencing depth of up-to 3000x with a total raw output of 10 GB per sample
Genomic testing for efficient cancer treatment & management
Offering world’s most trusted comprehensive genomic profiling test with in-depth insights on patients’ clinically relevant biomarkers and genomic alterations matching with FDA approved targeted therapies and immunotherapies.
OncoRx is a Next Generation Sequencing (NGS) based in vitro diagnostic test that uses targeted high throughput hybridization-based capture technology using DNA isolated from Formalin-Fixed Paraffin Embedded (FFPE) tumor tissue specimens and peripheral whole blood extracted circulating DNA.
It screens for Single Nucleotide Polymorphisms (SNPs), Insertion and Deletions (indels), Copy Number Alterations (CNAs) in 351 genes, select gene rearrangements, as well as genomic signatures including Homologous Recombination Repair (HRR) mutations, Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB).
Empowering physicians and patients with actionable and prescriptive insights for navigating cancer care.
As a trusted partner of choice in companion diagnostics, GenepoweRx helps to advance Personalized Healthcare in India by delivering diagnostic confidence through a broad range of genomic tests. Our standardized, fully-automated and cloud-supported solutions enable rapid turnaround time, empowering physicians to make the right treatment decisions more quickly.
SNV
Indels
CNVs
Fusions
TMB
MSI
HRR
Highlights
Next Generation Sequencing using Illumina
The proprietary Indian population specific database of variants
Official partners of MSK’s Precision Oncology Knowledge Base
OncoRx is registered as Class – C medical devices with CDSCO (Reg. No: Uppalu-Hy-der-TE/M/IVD/008407)
Strict quality control measures at different stages of sample processing, data acquisition and analysis adhering to international clinical laboratory practice guidelines
The test is validated in-house and the mean sequencing depth of the OncoRx is up-to 3000x with a total raw data output of 10 GB per sample
High throughput NGS data analysis, curation, and interpretation of the mutations are performed by well-experienced clinical scientists/genome analysts and cancer genome experts
REPORT
In addition to FDA approved therapies, OncoRx also offers clinically actionable, personalized Pharmacogenomics (PGx) & Nutrigenomics (NGx) report.
PGx report helps in prescribing the right medication by studying the CPIC & PharmGkb approved Biomarkers. NGx profile helps in structuring a personalized nutrition regimen based on an individual’s genetic profile and metabolism.
Simplified oncologist friendly report
Clinically actionable prescriptive insights to oncologists
Information on available active clinical trials
Nutrigenomics (NGx)
Druggable alterations and their associated FDA approved therapies
personalized Pharmacogenomics (PGx)
Recommended targeted therapies & possible mechanisms of resistance
OncoKB Therapeutic Levels of Evidence
Standard Care
01
FDA-recognized biomarker predictive of response to an FDA-approved drug in this indication
Investigational
02
Standard care biomarker recommended by the NCCN or other professional guidelines predictive of response to an FDA-approved drug in this indication
3A
Compelling clinical evidence supports the biomarker as being predictive of response to a drug in this indication
3B
Standard care or investigational biomarker predictive of response to a FDA-approved or investigational drug in another indication
Hypothetical
4
Compelling biological evidence supports the biomarker as being predictive of response to a drug
Standard Care Resistance
R1
Standard care biomarker predictive of resistance to an FDA-approved drug in this indication
Investigational Resistance
R2
Compelling clinical evidence supports the biomarker as being predictive of resistance to a drug
Biomarkers & FDA-Approved Therapy
Non-Small Cell Lung Cancer
EGFR exon 19 deletions & EGFR exon 21 , L858R alterations
Gilotrif® (afatinib), Iressa® (gefitinib), Tagrisso® (osimertinib), or Tarceva®
EGFR exon 20 T790M alterations
Tagrisso® (osimertinib)
ALK rearrangements
Alecensa® (alectinib), Alunbrig® (brigatinib) Xalkori® (crizotinib), or Zykadia® (ceritinib)
BRAF V600E
Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib)
MET single nucleotide variants (SNVs) and indels that lead to MET exon 14 skipping
TabrectaTM (capmatinib)
Breast Cancer
ERBB2 (HER2) amplification
Herceptin® (trastuzumab), Kadcyla® (ado trastuzumab-emtansine), or Perjeta® (pertuzumab)
PIK3CA C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y alterations
Piqray® (alpelisib)
Colorectal Cancer
KRAS wild-type (absence of mutations in codons 12 and 13)
Erbitux® (cetuximab)
KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)
Vectibix® (panitumumab)
Ovarian Cancer
BRCA1/2 alterations
Lynparza® (olaparib) or Rubraca® (rucaparib)
Prostate Cancer
Homologous Recombination Repair (HRR) gene (BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L) alterations
Lynparza® (olaparib)
All Solid Tumors
TMB ≥ 10 mutations per megabase
Keytruda® (pembrolizumab)
NTRK1/2/3 fusions
Vitrakvi® (larotrectinib)
- ABL1
- AKT1
- AKT2
- AKT3
- ALK
- ALOX12B
- AMER1
- APC
- AR
- ARAF
- ARFRP1
- ARID1A
- ASXL1
- ATM
- ATR
- ATRX
- AURKA
- AURKB
- AXIN1
- AXL
- BAP1
- BARD1
- BCL2
- BCL2L1
- BCL2L2
- BCL6
- BCOR
- BCORL1
- BRAF
- BRCA1
- BRCA2
- BRD4
- BRIP1
- BTG1
- BTG2
- BTK
- C11orf30
- CALR
- CARD11
- CASP8
- CBFB
- CBL
- CCND1
- CCND2
- CCND3
- CCNE1
- CD22
- CD274
- CD70
- CD79A
- CD79B
- CDC73
- CDH1
- CDK12
- CDK4
- CDK6
- CDK8
- CDKN1A
- CDKN1B
- CDKN2A
- CDKN2B
- CDKN2C
- CEBPA
- CHEK1
- CHEK2
- CIC
- CREBBP
- CRKL
- CSF1R
- CSF3R
- CTCF
- CTNNA1
- CTNNB1
- CUL3
- CUL4A
- CVR1B
- CXCR4
- CYP17A1
- DAXX
- DDR1
- DDR2
- DIS3
- DNMT3A
- DOT1L
- EED
- EGFR
- EP300
- EPHA3
- EPHB1
- EPHB4
- ERBB2
- ERBB3
- ERBB4
- ERCC4
- ERG
- ERRFI1
- ESR1
- EZH2
- FAM46C
- FANCA
- FANCC
- FANCG
- FANCL
- FAS
- FBXW7
- FGF10
- FGF12
- FGF14
- FGF19
- FGF23
- FGF3
- FGF4 ID3
- FGF6
- FGFR1
- FGFR2
- FGFR3
- FGFR4
- FH
- FLCN
- FLT1
- FLT3
- FOXL2
- FUBP1
- GABRA6
- GATA3
- GATA4
- GATA6
- GID4
- GNA11
- GNA13
- GNAQ
- GNAS
- GRM3
- GSK3B
- H3F3A
- HDAC1
- HGF
- HNF1A
- HRAS
- HSD3B1
- IDH1
- IDH2
- IGF1R
- IKBKE
- IKZF1
- INPP4B
- IRF2
- IRF4
- IRS2
- JAK1
- JAK2
- JAK3
- JUN
- KDM5A
- KDM5C
- KDM6A
- KDR
- KEAP1
- KEL
- KIT
- KLHL6
- KMT2A
- KMT2D
- KRAS
- LTK
- LYN
- MAF
- MAP2K1
- MAP2K2
- MAP2K4
- MAP3K1
- MAP3K13
- MAPK1
- MCL1
- MDM2
- MDM4
- MED12
- MEF2B
- MEN1
- MERTK
- MET
- MITF
- MKNK1
- MLH1
- MPL
- MRE11A
- MSH2
- MSH3
- MSH6
- MST1R
- MTAP
- MTOR
- MUTYH
- MYC
- MYCL
- MYCN
- MYD88
- NBN
- NF1
- NF2
- NFE2L2
- NFKBIA
- NKX2-1
- NOTCH1
- NOTCH2
- NOTCH3
- NPM1
- NRAS
- NT5C2
- NTRK1
- NTRK2
- NTRK3
- P2RY8
- PALB2
- PARK2
- PARP1
- PARP2
- PARP3
- PAX5
- PBRM1
- PDCD1
- PDCD1LG2
- PDGFRA
- PDGFRB
- PDK1
- PIK3C2B
- PIK3C2G
- PIK3CA
- PIK3CB
- PIK3R1
- PIM1
- PMS2
- POLD1
- POLE R
- PPARG
- PPP2R1A
- PPP2R2A
- PRDM1
- PRKAR1A
- PRKCI
- PTCH1
- PTEN
- PTOR
- PTPN11
- PTPRO
- QKI
- RAC1
- RAD21
- RAD51
- RAD51B
- RAD51C
- RAD51D
- RAD52
- RAD54L
- RAF1
- RARA
- RB1
- RBM10
- REL
- RET
- RICTOR
- RNF43
- ROS1
- SDHA
- SDHB
- SDHC
- SDHD
- SETD2
- SF3B1
- SGK1
- SMAD2
- SMAD4
- SMAR
- CA4
- SMARCB1
- SMO
- SNCAIP
- SOCS1
- SOX2
- SOX9
- SPEN
- SPOP
- SRC
- STAG2
- STAT3
- STK11
- SUFU
- SYK
- TBX3
- TEK
- TET2
- TGFBR2
- TIPARP
- TNFAIP3
- TNFRSF14
- TP53
- TSC1
- TSC2
- TYRO3
- U2AF1
- VEGFA
- VHL
- WHSC1
- WHSC1L1
- WT1
- XPO1
- XRCC2
- ZNF217
- ZNF703
- ALK introns 18, 19
- BRCA1 introns 2, 7, 8, 12, 16, 19, 20
- ETV4 intron 8
- EZR introns 9- 11
- KIT intron 16
- MYC intron 1
- RET introns 7-11
- SLC34A2 intron 4
- BCL2 3’UTR
- BRCA2 intron 2
- ETV5 introns 6,
- 7FGFR1 intron 1, 5, 17
- KMT2A (MLL) introns
- NOTCH2 intron 26
- TERC ncRNA
- PDGFRA introns 7, 9, 11
- ROS1 introns 31-35
- BCR introns 8, 13, 14
- MSH2 intron
- ETV6* introns 5, 6
- FGFR2 intron 1, 17
- NTRK1 introns
- 11RAF1 introns 4-8
- RSPO2 intron 1
- TERT Promoter
- BRAF introns 7-10
- EWSR7-introns 7-13
- FGFR3 intron 17
- MYB intron 14
- NTRK2 Intron 12
- RARA intron 2
- SDC4 intron 2
- TMPRSS2 introns 1- 3
List of Genes Screened in OncoRX Mini -
- ABL1
- ABL2
- ALK
- APLNR
- ATM
- B2M
- BARD1
- BRAF
- BRCA1
- BRCA2
- BRIP1
- CD274
- CD74
- CDK12
- CDKN2A
- CDKN2B
- CHEK1
- CHEK2
- EGFR
- EML4
- ERBB2
- ERG
- ETV1
- ETV4
- ETV5
- ETV6
- EZH2
- FANCA
- FANCC
- FANCD2
- FANCE
- FANCF
- FANCG
- FANCL
- FANCM
- FGFR2
- FGFR3
- FOXA1
- HLA-A
- HLA-B
- HLA-C
- IDH1
- IDH2
- KIT
- KRAS
- MET
- NAB2
- NF1
- NRAS
- NRG1
- NTRK1
- NTRK2
- NTRK3
- PALB2
- PDGFB
- PDGFRA
- PIK3CA
- PTEN
- RAD51B
- RAD51C
- RAD51D
- RAD54L
- RAF1
- RB1
- RET
- ROS1
- SLC34A2
- SMARCB1
- TERT
- TP53
- TSC1
- ALK
- BRAF
- EGFR
- ERBB2
- KIT
- MET
- PDGFRA
- PIK3CA
- RET
- EGFR
- KRAS
- NRAS
- NTRK1
- NTRK3
- PDGFRA
OncoRx is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies in accordance with the approved therapeutic product labeling.
Treating oncologists can also decide ideal candidates who can benefit from this test by means of immunotherapies, targeted therapies and personalized pharmacogenomic.
| Tests |
|---|
| Next-Generation Sequencing |
| MSK(Memorial Sloan Kettering) Cancer Center Knowledge Base |
| Number of Genes |
| Depth |
| Homologous Recombination Repair (HRR) |
| Programmed Death Ligand - 1 |
| Micro Satellite Instability (MSI) |
| Tumor Mutational Burden (TMB) |
| Pharmacogenomics |
| Nutrigenomics |
| Comprehensive | Mini | Condition Specific |
|---|---|---|
| 351 | 71 | 16-24 |
| 3000X | 1000X | 1000X |
Official Analytics partner
The world’s oldest and largest private cancer center, and GenePower(by K&H), partnered into collaboration that will utilize MSK’s clinical and research insights into gene mutations associated with solid tumors along with K&H proprietary database to provide accurate recommendations for Indian population .
Highlights
A directional test for tumor profiling enabling oncologists to predict response/ resistance to targeted and immuno-therapies for cancer patients over the traditional molecular testing.
Over 5600 genomic alterations covered-
We are the only company in Genomics space
lead by physicians in India.
Simplified reports
Open Discussion channel
between Oncologist, Pathologist and genomic specialist physician will lead to best treatment choices for the patient.
GenePower OncoRx uses targeted genomic sequencing and analysis to provide the physician with information on-
- Druggable mutations in your patient for which targeted
therapies are available. - Clinical trial match connector
- Microsatellite Instabilty status (MSI)
- Tumor Mutational Burden status (TMB)
- Sample required- FFPE tissue sample
- TAT(Turn Around Time)- 3- 4 weeks
Patients with stage 3 or stage 4 cancer who are looking to start targeted drug therapy.
When a patient is first diagnosed with cancer, it is suggested to take OncoRx test, prior to starting their chemotherapy treatment. The test enables the physician to identify the right drug regimen from the various FDA approved therapies. The response and management of the regimen is also analysed from the report enabling better decision-making for physicians.
OncoRx is India’s only test authenticated by FDA approved database developed by collecting longitudinal data over 20 years by clinicians/oncologists from MSK- Memorial Sloan Kettering Cancer Centre
Being the only company to be led by clinicians, we provide simple and precise reports that the clinicians are looking for when treating a patient. While maintaining precision in performance standards, decryption of data and quality control, the reports are automated with minimal turn-around-time.
OncoRx is testing solid tumours that uses next generation sequencing (NGS) to detect the four alterations known to drive cancer growth:
- SNP
- InDels (Insertions and Deletions)
- Copy number Variants (CNVs)
- Rearrangements or fusions
FAQs
A: Targeted therapies act on specific molecular targets associated with cancer which have proven evidence for the desired response and predicted outcomes. Standard chemotherapy on the other hand, act on rapidly dividing normal and cancerous cells.
A: Onco mini test aids physicians for oncotherapy decision making by screening a short panel with 71 cancer genes covering:
Level 1- FDA approved drugs for FDA approved biomarkers
Level 2- NCCN ratified standard care biomarker response to FDA approved drugs
R1 candidate genes - Standard care bio-markers with resistance to FDA approved drugs
It is generally recommended for a patient who is opting for chemotherapy.
OncoRx Test screens a large panel of over 353 potential genes assisting in predicting outcomes of FDA approved drug response, resistance, immunotherapy selection and management. The biomarkers covered are:
Level 1, Level 2 and Level 3 (Biomarkers with compelling clinical evidence to FDA approved or investigational drugs )
If a patient were to develop resistance of the ongoing chemotherapy it is recommended to choose OncoRx.
OncoRx is authenticated through collecting the world’s only FDA approved database which is developed by collecting real-time authorised data over 20+ years from Clinicians/ Oncologists of MSK. OncoRx also provides partnership opportunities to develop concrete databases, and 24/7 customer care representatives.
OncoRx provides the best second-line options for the patients as per the NCCN guidelines. We also provide clinical trial matches for the patients to enrol in leading institutions globally.
Single marker or Hotspot Mutation testing can detect only one alteration wherein OncoRx can provide insights on all four alterations known to drive cancer growth. The method of testing, therefore, takes a comprehensive approach to diagnosis and detailed reporting.
The biomarkers for non-small cell lung cancer, breast cancer, colorectal cancer, ovarian cancer, prostate cancer and all solid tumours are covered in the test. After identifying the specific biomarkers, the targeted FDA- approved therapies are selected.
An initial quality measure is performed in 3 days and processed only if the sample meets the OncoRx standards.
Helping us to deliver precise reports
